Wegovy contains semaglutide, a GLP-1 receptor agonist that acts on pathways involved in appetite regulation, glucose metabolism, and gastrointestinal function. The medicine is prescribed alongside reduced-calorie nutrition and increased physical activity for eligible patients requiring chronic weight management.

The supplied product is identified as a 2.4 mg strength with four pens described as a one-month supply. The precise administration schedule should follow the approved prescribing information rather than being inferred from the package description.

Common adverse effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Semaglutide also has important contraindications and precautions that should be considered before treatment.